Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, 210006, China
Location status: Recruiting
Location contact
Junshan Zhou, M.D.
CONTACT
Qiwen Deng, M.D.
CONTACT
NCT Number: NCT04175691
AISRNA is to analyze the expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with acute ischemic stroke and healthy control. The candidate circRNA/miRNA/lncRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Nanjing, Jiangsu, 210006, China
Location status: Recruiting
Junshan Zhou, M.D.
CONTACT
Qiwen Deng, M.D.
CONTACT
Noncoding RNAs have been highlighted to be involved in the pathological process of ischemic stroke (IS). The purpose of this protocol will investigate the expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with acute ischemic stroke and healthy control. The candidate circRNA/miRNA/lncRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke. Distinctive expression patterns of circRNA/miRNA/lncRNA will be identified by the next-generation sequencing and individual quantitative real time polymerase chain reaction (qRT-PCR). A diagnostic or predictive model will be established using logistic regression. The panel of these altered ncRNAs may be associated with acute IS and could serve as a novel diagnostic or predictive method.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases
Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)
Other names: Quantitative Real-time polymerase chain reaction
Time frame: 90 days
Differential expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) will be compared between AIS group and HC group, thus candidate circRNA/miRNA/lncRNA will be verified as biomarkers for the detection and prognosis of AIS.
Time frame: 90 days
The prognosis of AIS patients will be analyzed between differential expressed candidate miRNA/lncRNA after they have completed the systematic therapy.
Time frame: 7 days
Correlation of circRNA/miRNA/lncRNA and inflammatory factors on admission will be explored in acute ischemic stroke.
Time frame: 30 days
Correlation of circRNA/miRNA/lncRNA and stroke-associated infection will be explored in acute ischemic stroke.
Time frame: 90 days
Dynamic changes of circRNA/miRNA/lncRNA will be explored before and after endovascular therapy
Contact information is provided by the study sponsor or research team.
Junshan Zhou, M.D.
CONTACT
Qiwen Deng, M.D.
CONTACT
Nanjing First Hospital, Nanjing Medical University
Other
Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)
Acronym: AISRNA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07491952
Acute Stroke, Brain Diseases
Huntsville, Alabama, United States
View Trial DetailsNCT07627399
Acute Stroke, Body Temperature Changes
Antequera, Málaga, Spain
View Trial DetailsNCT05065216
Acute Stroke, Brain Diseases
Fairhope, Alabama, United States
View Trial DetailsNCT03318432
Acute Stroke, Brain Diseases
San Francisco, California, United States
View Trial Details